Lineage Cell Therapeutics Inc (AMEX: LCTX) is -13.00% lower on its value in year-to-date trading and has touched a low of $0.40 and a high of $1.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LCTX stock was last observed hovering at around $0.41 in the last trading session, with the day’s gains setting it 0.03%.
Currently trading at $0.44, the stock is -12.57% and -25.18% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.99 million and changing 6.37% at the moment leaves the stock -42.33% off its SMA200. LCTX registered -70.05% loss for a year compared to 6-month loss of -51.71%. The firm has a 50-day simple moving average (SMA 50) of $0.5846 and a 200-day simple moving average (SMA200) of $0.7585.
The stock witnessed a -17.94% gain in the last 1 month and extending the period to 3 months gives it a -11.85%, and is -12.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.23% over the week and 8.38% over the month.
Lineage Cell Therapeutics Inc (LCTX) has around 77 employees, a market worth around $99.83M and $9.50M in sales. Profit margin for the company is -195.90%. Distance from 52-week low is 9.01% and -71.97% from its 52-week high. The company has generated returns on investments over the last 12 months (-23.34%).
with sales reaching $1.72M over the same period.The EPS is expected to shrink by -4.76% this year, but quarterly earnings will post 18.72% year-over-year. Quarterly sales are estimated to grow 19.11% in year-over-year returns.
150.0 institutions hold shares in Lineage Cell Therapeutics Inc (LCTX), with institutional investors hold 54.20% of the company’s shares. The shares outstanding are 228.36M, and float is at 227.36M with Short Float at 9.83%. Institutions hold 53.91% of the Float.
The top institutional shareholder in the company is BROADWOOD CAPITAL INC with over 41.67 million shares valued at $41.55 million. The investor’s holdings represent 22.0675 of the LCTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.56 million shares valued at $9.53 million to account for 5.0629 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 8.47 million shares representing 4.6329 and valued at over $8.45 million, while DEFENDER CAPITAL, LLC. holds 2.6338 of the shares totaling 4.97 million with a market value of $4.96 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
The most recent transaction is an insider purchase by BROADWOOD PARTNERS, L.P., the company’s Director. SEC filings show that BROADWOOD PARTNERS, L.P. bought 7,894,737 shares of the company’s common stock on Jan 27 ’25 at a price of $0.76 per share for a total of $6.0 million. Following the purchase, the insider now owns 49.56 million shares.
Lineage Cell Therapeutics Inc disclosed in a document filed with the SEC on Nov 26 ’24 that Howe Jill Ann (Chief Financial Officer) bought a total of 15,000 shares of the company’s common stock. The trade occurred on Nov 26 ’24 and was made at $0.59 per share for $8850.0. Following the transaction, the insider now directly holds 25500.0 shares of the LCTX stock.
Still, SEC filings show that on Nov 26 ’24, Samuel George A. III (General Counsel) acquired 15,000 shares at an average price of $0.60 for $9000.0. The insider now directly holds 22,184 shares of Lineage Cell Therapeutics Inc (LCTX).
